Inflammatory Disease clinical trials

Explore recruiting inflammatory disease clinical trials.

Recruiting inflammatory disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Inflammatory Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis

Germany, France, Netherlands, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus-negative myocarditis or inflammatory cardiomyopathy (IMPROVE-MC).

Poland

Therapeutic use (Phase IV) EU CTIS Study details

REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in newly diagnosed PolyMyalgia Rheumatica

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in relapsing PolyMyalgia Rheumatica

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Inflammatory Disease trials by city

Inflammatory Disease in Toronto Inflammatory Disease in Vancouver Inflammatory Disease in Montreal Inflammatory Disease in Calgary Inflammatory Disease in Edmonton Inflammatory Disease in Ottawa Inflammatory Disease in Winnipeg Inflammatory Disease in Quebec City Inflammatory Disease in Hamilton Inflammatory Disease in Kitchener Inflammatory Disease in London Inflammatory Disease in Halifax Inflammatory Disease in New York Inflammatory Disease in Los Angeles Inflammatory Disease in Chicago Inflammatory Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease